Eupraxia Pharmaceuticals Inc.'s SEC filings document a clinical-stage biotechnology issuer reporting current events on Form 6-K, with Form 40-F status indicated in the filings. Recent reports furnish press releases and exhibits covering the Diffusphere drug-delivery platform, EP-104GI clinical disclosures in eosinophilic esophagitis, RESOLVE trial scoring measures such as EREFS and EoEHSS, and scientific-meeting presentations.
The filings also record governance and securityholder matters, including executive medical leadership changes, annual general meeting notice materials, voting and record-date mechanics for common shares, and issuer identifiers such as CUSIP and ISIN. These disclosures frame Eupraxia's public-company record around clinical development, governance, and common-share voting matters.
Eupraxia Pharmaceuticals Inc. (EPRX) reached its target enrollment of 120 patients in the blinded, placebo-controlled Phase 2b portion of the RESOLVE trial for EP-104GI in eosinophilic esophagitis. It enrolled and treated its 120th patient on October 12, 2026. Patients who completed screening and qualification may still be dosed, so the final number dosed may exceed 120.
Periodic data reviews found that the planned sample size does not need adjustment. Across the Phase 1b/2a and Phase 2b portions, over 3,000 injections of EP-104GI or vehicle have been administered, with no treatment-related serious adverse events to date. The Phase 2b interim analysis is expected in December 2026 and is to cover symptoms, histologic findings and safety for the first 60 patients to reach six months, with data also available at 3-, 9- and 12-month timepoints. EP-104GI remains investigational; its effects have not been established and require clinical study.
Eupraxia Pharmaceuticals Inc. announced that three abstracts on EP-104GI in its ongoing Phase 1b/2 RESOLVE trial were accepted for presentation at ACG 2026 and UEG Week 2026. The ACG poster is scheduled for October 12, 2026; UEG presentations are scheduled for October 18 and October 19, 2026. The abstract titles describe dysphagia improvements up to 52 weeks and improvements in histopathological features after a single administration.
The Phase 1b/2a study is multicenter, open-label and dose-escalation, evaluating safety, tolerability, pharmacokinetics and efficacy; treatment is a single dose delivered through 4 to 20 esophageal wall injections. The randomized, placebo-controlled Phase 2b portion is recruiting at 120mg and 160mg doses, with interim data expected in December 2026. Eupraxia also plans to disclose additional Phase 1b/2a data in the coming months.
Eupraxia Pharmaceuticals Inc. reported updated results from the open-label Phase 1b/2a RESOLVE study of EP-104GI for eosinophilic esophagitis. In the highest-dose Cohort 9, 2 of 3 patients (66%) maintained clinical remission at 52 weeks after one administration; across cohorts 5–9, 9 of 14 patients (64%) remained in remission at 52 weeks.
At 36 weeks, Cohort 8b had mean EoEHSS stage and grade reductions of -0.26 and -0.27, respectively, and a mean SDI reduction of 3.3. Cohort 9 had a mean SDI reduction of 3.0 at both 36 and 52 weeks. The company reported no treatment-emergent or procedure-related serious adverse events, or cases of oropharyngeal candidiasis, adrenal insufficiency or glucose derangement. The Phase 2b study is recruiting at 120 mg and 160 mg doses, with interim data expected in December 2026.
Eupraxia Pharmaceuticals Inc. (EPRX) announced that its common shares have commenced trading on the Nasdaq Global Select Market, having transferred from the Nasdaq Capital Market, while continuing to trade on the Toronto Stock Exchange under the same ticker. No action is required by shareholders in connection with the transfer. Management stated that meeting Nasdaq’s highest market tier requirements reflects the company’s progress as it advances its clinical programs.
The company also plans to engage investors through several conferences in New York in September 2026, including events hosted by Cantor, H.C. Wainwright and Morgan Stanley, featuring fireside chats, company presentations and one-on-one meetings.
Eupraxia Pharmaceuticals Inc. (EPRX) has filed an amended Form F-10 short form base shelf prospectus to register up to US$300,000,000 of common shares, preferred shares, debt securities, warrants, subscription receipts and units. Securities may be offered by Eupraxia or selling securityholders, separately or together, over a 25‑month period, including via underwritten deals, private sales or an at‑the‑market distribution.
Eupraxia is a clinical‑stage biotechnology company using its Diffusphere™ delivery technology, with lead programs EP‑104GI for eosinophilic esophagitis and EP‑104IAR for knee osteoarthritis. As of June 30, 2026, it held $52.4 million in cash and cash equivalents and anticipates funding operations into the second half of 2028, while disclosing a history of negative operating cash flow and ongoing capital needs.
The prospectus highlights significant risks, including speculative investment characteristics, dilution from additional equity, limited liquidity in some securities, PFIC-related U.S. tax exposure, dependency on EP‑104GI and EP‑104IAR development and the challenges of obtaining regulatory approvals across multiple jurisdictions under the MJDS framework.
Manchester Management Company, LLC, Manchester Management PR, LLC, Manchester Explorer, L.P., James E. Besser, and Morgan C. Frank report their ownership of common shares of Eupraxia Pharmaceuticals Inc. on an amended Schedule 13G (Amendment No. 3).
Reported beneficial ownership includes 2,634,048 shares (4.3% of the class) for each of Manchester Management Company, LLC and Manchester Management PR, LLC, 2,511,121 shares (4.1%) for Manchester Explorer, L.P., 2,772,341 shares (4.5%) for James E. Besser, and 2,664,780 shares (4.3%) for Morgan C. Frank. Besser has sole voting and dispositive power over 138,293 shares and Frank over 153,659 shares, with the remainder held under shared voting and dispositive power.
The filing states that, other than the shares over which Besser and Frank have sole power, all reported securities are directly owned by advisory clients of Manchester Management PR, LLC and that none of these advisory clients may be deemed to beneficially own more than 5% of Eupraxia’s common shares. Each reporting person disclaims beneficial ownership beyond their pecuniary interest.
Eupraxia Pharmaceuticals Inc. reported new symptom-response data from the Phase 1b/2a RESOLVE trial of EP-104GI in adults with eosinophilic esophagitis. In Cohorts 7–9, the proportion of patients with moderate or severe odynophagia fell from 62% at baseline to 25% at 24–52 weeks, and severe odynophagia (23% at baseline) was absent at 24 and 52 weeks. For dysphagia, moderate or severe symptoms decreased from 77% at baseline to 25% at 24 and 52 weeks. At 52 weeks, 50% of patients reported no odynophagia versus 15% at baseline. EP-104GI has been administered to over 130 patients (more than 2,000 injection sites) with no treatment-emergent or procedure-related Serious Adverse Events reported. A randomized Phase 2b portion of RESOLVE using 120 mg and 160 mg doses is ongoing, with an interim readout expected in Q4 2026.
Eupraxia Pharmaceuticals Inc. reported a six-month 2026 net loss of $27.1 million, wider than $15.5 million a year earlier, driven by sharply higher research and development spending of $24.0 million and general and administrative expenses of $10.1 million as EP‑104GI and platform programs advanced.
Liquidity strengthened after a February 20, 2026 overnight marketed equity offering of 7,607,145 common shares and 1,428,571 pre‑funded warrants, generating about $58.6 million net. At June 30, 2026, cash and cash equivalents were $52.4 million and short‑term investments $81.2 million, versus current liabilities of $8.6 million.
The company remains pre‑revenue with an accumulated deficit of $196.7 million and discloses continued dependence on external financing, partnerships and potential non‑dilutive funding. Clinical work focuses on the RESOLVE trial of EP‑104GI for eosinophilic esophagitis, while development and partnering for EP‑104IAR for osteoarthritis are currently paused.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company based in Vancouver, has filed a short form base shelf prospectus and accompanying Form F-10 to register up to US$300,000,000 of common shares, preferred shares, debt securities, warrants, subscription receipts and units. These securities may be offered over a 25‑month period by the company or its securityholders, separately or together, including through underwritten offerings or an at-the-market distribution. Common shares trade on the TSX and Nasdaq under “EPRX,” with recent closing prices of C$8.98 and US$6.51, respectively. The filing highlights significant risks, including potential dilution from additional equity, limited liquidity for non-common-share securities, PFIC-related U.S. tax consequences, dependence on lead candidates EP‑104GI and EP‑104IAR, and the need for substantial additional capital.